Jordi Rodon

Summary

Publications

  1. doi request reprint Molecular prescreening to select patient population in early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Spain
    Nat Rev Clin Oncol 9:359-66. 2012
  2. doi request reprint Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial
    J Rodon
    Vall D Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Oncol 26:1791-8. 2015
  3. pmc Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
    Jordi Rodon
    Medical Oncology, Vall d Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain
    Invest New Drugs 33:357-70. 2015
  4. pmc First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
    Jordi Rodon
    Medical Oncology, Vall d Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 21:553-60. 2015
  5. doi request reprint Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Jordi Rodon
    Vall d Hebron University Hospital, Barcelona, Spain
    Invest New Drugs 32:670-81. 2014
  6. doi request reprint Development of PI3K inhibitors: lessons learned from early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:143-53. 2013
  7. pmc Combining targeted therapies: practical issues to consider at the bench and bedside
    Jordi Rodon
    Servei d Oncologia Medica, Hospital Universitari Vall d Hebron, Vall d Hebron Institute of Oncology V H I O, Passatge Vall d Hebron 119, 08035 Barcelona, Spain
    Oncologist 15:37-50. 2010
  8. pmc Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncologist 16:1729-40. 2011
  9. doi request reprint Biomarker-driven patient selection for early clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
    Curr Opin Oncol 25:305-12. 2013
  10. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011

Collaborators

Detail Information

Publications17

  1. doi request reprint Molecular prescreening to select patient population in early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Spain
    Nat Rev Clin Oncol 9:359-66. 2012
    ....
  2. doi request reprint Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial
    J Rodon
    Vall D Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Oncol 26:1791-8. 2015
    ..These various obstacles should be addressed to test and then implement precision medicine in cancer. ..
  3. pmc Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
    Jordi Rodon
    Medical Oncology, Vall d Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain
    Invest New Drugs 33:357-70. 2015
    ..Conclusion Based on the PK, PD, and biomarker evaluations, the intermittent administration of galunisertib at 300 mg/day is safe for future clinical investigation...
  4. pmc First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
    Jordi Rodon
    Medical Oncology, Vall d Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 21:553-60. 2015
    ..To use LY2157299 in the treatment of malignancies, we investigated its properties in a first-in-human dose (FHD) study in patients with cancer...
  5. doi request reprint Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Jordi Rodon
    Vall d Hebron University Hospital, Barcelona, Spain
    Invest New Drugs 32:670-81. 2014
    ..This first-in-man study was initiated to identify the maximum tolerated dose (MTD) of buparlisib (100 mg/day) and to assess safety and preliminary efficacy...
  6. doi request reprint Development of PI3K inhibitors: lessons learned from early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:143-53. 2013
    ..We also discuss key unresolved translational questions related to the clinical development of inhibitors of the PI3K/AKT/mTOR pathway and propose designs for biomarker-driven trials to address those issues...
  7. pmc Combining targeted therapies: practical issues to consider at the bench and bedside
    Jordi Rodon
    Servei d Oncologia Medica, Hospital Universitari Vall d Hebron, Vall d Hebron Institute of Oncology V H I O, Passatge Vall d Hebron 119, 08035 Barcelona, Spain
    Oncologist 15:37-50. 2010
    ..Recent technologies, such as multiplexed assay platforms and bioinformatics, will shape the future of clinical trials and help answer these questions surrounding combinatorial treatment...
  8. pmc Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncologist 16:1729-40. 2011
    ..Ultimately, the predictive value of a side effect of molecular targeted therapies requires validation in prospective trials...
  9. doi request reprint Biomarker-driven patient selection for early clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
    Curr Opin Oncol 25:305-12. 2013
    ..Technical and logistical obstacles that may hinder progress of this approach will be discussed, along with the ethical and financial concerns...
  10. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011
    ..This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose...
  11. doi request reprint Genomic medicine frontier in human solid tumors: prospects and challenges
    Rodrigo Dienstmann
    Vall d Hebron University Hospital, P Vall d Hebron 119 122, Barcelona, Spain 08035
    J Clin Oncol 31:1874-84. 2013
    ....
  12. doi request reprint Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors
    Rodrigo Dienstmann
    Authors Affiliations Molecular Therapeutics Research Unit, Medical Oncology Department and Experimental Therapeutics Group, Vall d Hebron University Hospital, Barcelona, Spain
    Mol Cancer Ther 13:1021-31. 2014
    ..Here, we provide a review of the literature, with the aim of differentiating the genomic contexts in which these various types of inhibitors may potentially have superior activity...
  13. ncbi request reprint Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2
    Rodrigo Dienstmann
    Medical Oncology Service, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain
    Recent Pat Anticancer Drug Discov 6:210-36. 2011
    ..This review will focus primarily on an analysis of newly developed inhibitors of this pathway that have entered clinical trials, and recently registered patents in this field...
  14. doi request reprint Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 11:2062-71. 2012
    ..2%). These results suggest that matching chemorefractory patients with colorectal cancer with targeted agents in phase I trials based on the current molecular profile does not confer a significant clinical benefit...
  15. doi request reprint A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer
    Analia Azaro
    Vall d Hebron University Hospital and University of Autònoma, Barcelona, Spain
    Invest New Drugs 33:710-9. 2015
    ..There was minimal antitumor activity against the model, CRC 019. Avatar models showed minimal pharmacodynamic effects consistent with the observed antitumor effects. This study suggests a dose of LY2780301 500 mg QD for future studies...
  16. doi request reprint The Personalization of Therapy: Molecular Profiling Technologies and Their Application
    Jorge Zeron-Medina
    Vall d Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain
    Semin Oncol 42:775-87. 2015
    ..This article aims to summarize the different biomarker applications and discuss the current challenges along with the major technologies presently used in clinical practice. ..
  17. doi request reprint Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors
    Cinta Hierro
    Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Semin Oncol 42:801-19. 2015
    ..Further studies are warranted to establish the predictive significance of the different FGFR-aberrations and to incorporate them into clinical algorithms, now that second-generation, selective FGFR inhibitors exist. ..